NasdaqCM - Delayed Quote USD

Moleculin Biotech, Inc. (MBRX)

4.3500 -0.2500 (-5.43%)
At close: April 24 at 4:00 PM EDT
4.2800 -0.07 (-1.61%)
After hours: April 24 at 7:31 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Walter V. Klemp Founder, Chairman, President & CEO 894.54k -- 1960
Mr. Jonathan P. Foster CPA Executive VP & CFO 611.17k -- 1964
Dr. Donald H. Picker Ph.D. Chief Scientific Officer 486.44k -- 1946
Dr. Waldemar Priebe Ph.D. Co-Founder, Founding Scientist & Chairman of Scientific Advisory Board -- -- --
Dr. Robert C. Shepard FACP, M.D. Chief Medical Officer of Annamycin -- -- 1952
Dr. John Paul Waymack M.D., Sc.D. Senior Chief Medical Officer -- -- 1952
Dr. Sandra L. Silberman M.D., Ph.D. Chief Medical Officer of New Products -- -- 1956
Dr. Wolfram C. M. Dempke M.B.A., M.D., Ph.D. European Chief Medical Officer -- -- --
Ms. Jacqueline Northcut Consultant 51.11k -- 1962
Mr. Louis Ploth Jr. Independent Advisor 118.49k -- 1954

Moleculin Biotech, Inc.

5300 Memorial Drive
Suite 950
Houston, TX 77007
United States
(713) 300-5160 https://moleculin.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
18

Description

Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.

Corporate Governance

Moleculin Biotech, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 09, 2024 - May 13, 2024
Moleculin Biotech, Inc. Earnings Call

Related Tickers

PHRRF PharmaTher Holdings Ltd.
0.1670
+0.27%
 
PHRM.CN PharmaTher Holdings Ltd.
0.2350
+4.44%
 
SNGX Soligenix, Inc.
0.3830
-4.25%
 
NRBO NeuroBo Pharmaceuticals, Inc.
3.1000
+2.65%
 
PULM Pulmatrix, Inc.
2.0201
-3.34%
 
RNAC Cartesian Therapeutics, Inc.
20.72
+0.63%
 
TENX Tenax Therapeutics, Inc.
3.5600
+0.85%
 
TCON TRACON Pharmaceuticals, Inc.
1.8900
+2.16%
 
UNCY Unicycive Therapeutics, Inc.
1.0400
-2.80%
 
CNSP CNS Pharmaceuticals, Inc.
0.2140
+1.90%